Hong Kong Publicly Listed Pharma signs CBD Supply Deal
August 02 2019 - 8:08AM
InvestorsHub Cannabis NewsWire
Hong Kong Publicly Listed Pharma
signs CBD Supply Deal
"CBD exclusive Supply
deal signed between public HK Pharmaceutical Group ‘SANAI’ &
Asia HEMP Company
'CANNACUBED''
August 2, 2019 -- InvestorsHub NewsWire --
Asia’s fastest growing ‘Cannabis’ company – ‘CannAcubed
Pte Ltd’ delivered its first CBD supply order to one of Hong
Kong’s most respected publicly listed pharmaceutical Companies –
‘Sanai Health Industry Group Company
Limited’.
An undisclosed volume
of pure pharmaceutical grade 99.99% CBD isolate was successfully
delivered to Sanai’s Head office in HK last week, with the 2
parties having already signed an exclusive supply deal between them
several months prior.
Sanai Health Industry
Group Company Limited is a listed company
trading in the Hong Kong Stock Exchange (Stock code:
1889.hk). The Group provides a range of comprehensive
products and services across the health care industry. In
mainland China, the Group owns a GMP standard pharmaceutical plant,
and maintain an extensive distribution network for pharmaceutical
products nationwide. Sanai Health also owns a genetic testing
laboratory in Hong Kong and is heavily
engaged in the cannabidiol (CBD)
business.
CannAcubed
Pte Ltd is a fully integrated Industrial Hemp company with global
headquarters in Singapore, and a presence in Hong Kong, China,
Israel & Los Angeles.
CannAcubed
was China’s first foreign company to successfully set up and
establish its Hemp cultivation & CBD production project in
Yunnan, China; And is the only Cannabis company in China to be
fully licensed across the entire value chain, including research
& development, cultivation, storage and transport,
production and processing, manufacturing, and
import/export.
The Groups
unique selling proposition (USP) is its 3 point base closed loop
system which includes Cultivation (intelligent Agriculture 4.0),
Product Base (CBD Hemp Beer, CBD Cosmetics, CBD cigarettes, New
Materials, Fibre, and Hemp Food), and IP & Technology where the
company is developing China’s first Cannabis Traceability platform
with some of China’s largest Tech, Internet & Mobile
partners.
“This is a milestone achievement for us here in
Asia”, said Glenn Davies - Group CEO of CannAcubed. “We worked very
closely with the Sanai executive team to ensure the end product met
every safety and regulatory standard for their group and the HK
market around compliance. It’s just the beginning now, and this
lays the foundation to move quickly on greater supply and other
products for Sanai Health and the wider Hong Kong market” stated
Davies
“As
a publicly listed pharmaceutical company in HK, it was absolutely
imperative we partnered with a Group that could deliver the
quality, standards and product purity we required for the HK
market! CannAcubed exceeded our expectations in this regard and we
couldn’t be happier” announced Fred Cheng, Director of Sanai Health
Group. “We had unique requirements and very strict guidelines on
what could and what couldn’t be accepted into the HK market. The
global CannAcubed team worked through the entire process with us
with complete visibility and transparency and laid the ground work
for a solid long-term partnership.” Mr Cheng
replied.
The
2 parties now intend to work together on new product development
and distribution into the HK and wider Asia market, as Sanai Health
looks to become one of HK’s leading manufacturer and suppliers of
quality CBD related products.
Initial focus will be around CBD cosmetics,
health & pharamecutical related products, and eventually food
& beverage supplements.
If you would like more
information about this topic, please call Glenn Davies on
+6596447032, or email – glenn@cannacubed.com.